Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Caribou Biosciences, Inc. (CRBU)

4.96   -0.08 (-1.59%) 03-17 16:00
Open: 4.98 Pre. Close: 5.04
High: 5.05 Low: 4.83
Volume: 1,265,604 Market Cap: 304(M)

Technical analysis

as of: 2023-03-20 7:44:48 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.2     One year: 8.17
Support: Support1: 4.82    Support2: 4.01
Resistance: Resistance1: 6.17    Resistance2: 7
Pivot: 5.6
Moving Average: MA(5): 5.13     MA(20): 5.75
MA(100): 7.52     MA(250): 8.18
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 11.3     %D(3): 14.6
RSI: RSI(14): 27.8
52-week: High: 13.18  Low: 4.82
Average Vol(K): 3-Month: 508 (K)  10-Days: 570 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CRBU ] has closed above bottom band by 10.2%. Bollinger Bands are 16.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.06 - 5.09 5.09 - 5.12
Low: 4.74 - 4.79 4.79 - 4.82
Close: 4.89 - 4.96 4.96 - 5.01

Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Headline News

Mon, 20 Mar 2023

Sun, 19 Mar 2023
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ... - Digital Journal

Fri, 17 Mar 2023
These 4 Biotech Stocks Just Got ‘Fast Track’ Designation Greenlights - Yahoo Canada Finance

Mon, 13 Mar 2023
Oppenheimer Comments on Caribou Biosciences, Inc.'s Q1 2024 ... - MarketBeat

Thu, 09 Mar 2023
7 Top Gene-Editing Stocks to Buy - WTOP

Thu, 09 Mar 2023
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 48 (M)
% Held by Insiders 10.8 (%)
% Held by Institutions 73 (%)
Shares Short 4,280 (K)
Shares Short P.Month 4,370 (K)

Stock Financials

EPS -1.56
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.92
Profit Margin (%) 0
Operating Margin (%) -768.2
Return on Assets (ttm) -16.3
Return on Equity (ttm) -28.9
Qtrly Rev. Growth 44.2
Gross Profit (p.s.) -1.12
Sales Per Share 0.22
EBITDA (p.s.) -1.71
Qtrly Earnings Growth 0
Operating Cash Flow -91 (M)
Levered Free Cash Flow -56 (M)

Stock Valuations

PE Ratio -3.18
PEG Ratio 0.2
Price to Book value 1
Price to Sales 21.95
Price to Cash Flow -3.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.